Furthermore, we found that in both CTLA4- PD1- (P = 0.0002) and CTLA4- PD1+ (P = 0.018) subgroups, cluster 1 gastric cancer patients had a higher immunophenoscore (IPS), indicating better immunotherapy response (31) (Figures 2H, I). Here, CTLA4 is linked to gastric cancer.